Format

Send to

Choose Destination
Cell Transplant. 2000 May;9(3):307-317. doi: 10.1177/096368970000900302.

In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients.

Author information

1
Dendreon Corporation, Seattle, WA 98121.
2
Center for AIDS Research, Stanford University Medical Center, Stanford, CA 94305.
3
Stanford Medical School Blood Center, Stanford, CA 94034.

Abstract

Peripheral blood samples from HIV-seropositive individuals enrolled in a pilot clinical trial investigating the use of allogeneic dendritic cell therapy were evaluated for mixed chimerism. In this study, dendritic cells from HLA-identical, HIV-seronegative siblings were used. Patients received an infusion of dendritic cells pulsed with HIV MN gp160 protein or with peptides from HLA-A2 restricted epitopes of env, gag, and pol proteins every month for 6-9 months. Of the five allogeneic dendritic cell recipients, two showed increases in HIV antigen-specific immune responses. Allele-specific polymorphisms were identified in three sib-pairs that allowed infused donor cells to be detected using sensitive PCR-based molecular methods. Analysis of blood samples from patients showed similar patterns of donor cell persistence after the first infusion, in that cells were detectable for at least 1 week. Also, differences were observed in the kinetics of cell survival between the first and subsequent infusion cycles in all three patients. This suggests variation in HIV-specific immune responses detected among these three patients was not due to differences in persistence of infused donor cells.

KEYWORDS:

Allele-specific polymorphism; Cell survival; Dendritic cells; Mixed chimerism

PMID:
28880658
DOI:
10.1177/096368970000900302

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center